GHRA vertical no logo GHRA 2017 Awardee collage edited


Congratulations, Awardees!



Tim Walbert for siteThe Cures Within Reach Patient Impact Industry Award is being presented to Timothy P. Walbert, Chairman, President and Chief Executive Officer of Horizon Pharma plc, for his commitment to pursuing treatments for rare diseases, and his belief that repurposing is part of the solution. Tim has guided Horizon from an idea to a successful biopharmaceutical company in a short period of time. Moreover, he and his team at Horizon are laser focused on the rare disease community.

Read Timothy P. Walbert's bio

Blog Post: Meet Timothy P. Walbert, the CEO of Horizon Pharma plc - On a Mission to Help Rare Disease Patients




Sylvia Anderson for siteBerish Rubin for siteThe Janet Davison Rowley Patient Impact Research Award is being conferred upon Drs. Berish Rubin and Sylvia Anderson, who jointly direct the Laboratory for Familial Dysautonomia (FD) Research at Fordham University.  Drs. Rubin and Anderson and their team discovered the gene mutation for Familial Dysautonomia (FD), a rare disorder that impacts the development and function of the autonomic nervous system in affected individuals because of the loss of functional IKAP protein. They were then able to restore IKAP function through repurposing 1) two bioactive agents from soy; 2) derivatives of Vitamin A and E; and 3) EGCG, a bioactive agent found in green tea. Their repurposing research has been published in the numerous journals, including Molecular Nutrition & Food Research.

Read Dr. Berish Rubin's bio

Read Dr. Sylvia Anderson's bio

Blog Post: Fordham Professors Find Nutraceutical Treatments For Rare Disease


Michael Tranfaglia for siteThe Golan Christie Taglia Patient Impact Philanthropy Award is awarded to the FRAXA Research Foundation, a nonprofit committed to finding a cure for Fragile X syndrome. Fragile X is a rare disease that is the most common known cause of autism worldwide. Dr. Michael Tranfaglia, FRAXA's co-founder, will be accepting this award on his organization's behalf. FRAXA has invested significantly in repurposing research, and Dr. Tranfaglia's son, who has Fragile X, is treated with a repurposed therapy.

Read Dr. Michael Tranfaglia's bio 

Blog Post: Global Health Repurposing Philanthropic Award Goes To FRAXA Research Foundation


Lieven Lagae for site

 The Cures Within Reach Industry Patient Impact Clinical Award, a new award this year, will be given to Dr. Lieven Lagae of KUL University Hospitals, a pediatric neurologist for his research on Dravet Syndrome, a severe seizure disorder.  Dr. Lagae is a pioneer in research repurposing the drug fenfluramine for Dravet.  This drug was part of the Phen-Fen diet drug that was taken off the market, and fenfluramine, which was helping Dravet patients, was no longer available.  Dr. Lagae has doggedly fought to bring Dravet patients access to this drug, and is leading a worldwide effort to secure regulatory approval for fenfluramine so that it will help stop these debilitating seizures.

Read Dr. Lieven Lagae's bio

Blog Post: Dr. Lieven Lagae Leads Fight to Bring Fenfluramine to Market for Dravet Patients


Click here to sign up for our eNewsletter today!

Please include your Full Name* and Email Address*


If the link above doesn't work, please contact our Admin support at with your Full Name and Email Address to sign up!


Cures Within Reach

134 N. LaSalle, #1130
Chicago, IL 60602

All funds donated to Cures Within Reach may be tax deductible for federal income tax purposes. 

Partnership for Cures DBA Cures Within Reach is recognized by the IRS as a 501(c)3 tax-exempt not-for-profit organization, tax ID 20-3620169.


Saturday the 18th. Copyright 2018 Cures Within Reach.